These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 8836935)

  • 1. Motor actions of eliprodil in the normal and monoamine-depleted mouse: a role in the treatment of Parkinson's disease?
    Brooks S; Kaur S; Starr BS; Starr MS
    J Neural Transm (Vienna); 1996; 103(6):737-48. PubMed ID: 8836935
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antiparkinsonian action of dextromethorphan in the reserpine-treated mouse.
    Kaur S; Starr MS
    Eur J Pharmacol; 1995 Jul; 280(2):159-66. PubMed ID: 7589181
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of the effects of NMDA and AMPA antagonists on the locomotor activity induced by selective D1 and D2 dopamine agonists in reserpine-treated mice.
    Starr MS; Starr BS
    Psychopharmacology (Berl); 1994 Apr; 114(3):469-76. PubMed ID: 7855205
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Motor effects of lamotrigine in naive and dopamine-depleted mice.
    Kaur S; Starr M
    Eur J Pharmacol; 1996 May; 304(1-3):1-6. PubMed ID: 8813577
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Facilitation of dopamine D1 receptor- but not dopamine D1/D2 receptor-dependent locomotion by glutamate antagonists in the reserpine-treated mouse.
    Starr MS; Starr BS
    Eur J Pharmacol; 1993 Dec; 250(2):239-46. PubMed ID: 7906652
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Potentiation of dopamine-dependent locomotion by clonidine in reserpine-treated mice is restricted to D2 agonists.
    Starr MS; Starr BS
    J Neural Transm Park Dis Dement Sect; 1994; 7(2):133-42. PubMed ID: 7710665
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Locomotor effects of amantadine in the mouse are not those of a typical glutamate antagonist.
    Starr MS; Starr BS
    J Neural Transm Park Dis Dement Sect; 1995; 9(1):31-43. PubMed ID: 7605588
    [TBL] [Abstract][Full Text] [Related]  

  • 8. N-methyl-D-aspartate receptor blockade attenuates D1 dopamine receptor modulation of neuronal activity in rat substantia nigra.
    Huang KX; Bergstrom DA; Ruskin DN; Walters JR
    Synapse; 1998 Sep; 30(1):18-29. PubMed ID: 9704877
    [TBL] [Abstract][Full Text] [Related]  

  • 9. MK-801 alters the effects of priming with L-DOPA on dopamine D1 receptor-induced changes in neuropeptide mRNA levels in the rat striatal output neurons.
    Van De Witte SV; Groenewegen HJ; Voorn P
    Synapse; 2002 Jan; 43(1):1-11. PubMed ID: 11746728
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CY 208-243 behaves as a typical D-1 agonist in the reserpine-treated mouse.
    Abbott B; Starr BS; Starr MS
    Pharmacol Biochem Behav; 1991 Feb; 38(2):259-63. PubMed ID: 1676166
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of coadministration of glutamate receptor antagonists and dopaminergic agonists on locomotion in monoamine-depleted rats.
    Gossel M; Schmidt WJ; Löscher W; Zajaczkowski W; Danysz W
    J Neural Transm Park Dis Dement Sect; 1995; 10(1):27-39. PubMed ID: 8619907
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Adenosine A1 receptor blockade selectively potentiates the motor effects induced by dopamine D1 receptor stimulation in rodents.
    Popoli P; Giménez-Llort L; Pezzola A; Reggio R; Martínez E; Fuxe K; Ferré S
    Neurosci Lett; 1996 Nov; 218(3):209-13. PubMed ID: 8945765
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Actions at sites other than D(3) receptors mediate the effects of BP897 on l-DOPA-induced hyperactivity in monoamine-depleted rats.
    Visanji NP; Millan MJ; Brotchie JM
    Exp Neurol; 2006 Nov; 202(1):85-92. PubMed ID: 16814282
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Glutamate antagonists modify the motor stimulant actions of D1 and D2 agonists in reserpine-treated mice in complex ways that are not predictive of their interactions with the mixed D1/D2 agonist apomorphine.
    Starr MS; Starr BS
    J Neural Transm Park Dis Dement Sect; 1993; 6(3):215-26. PubMed ID: 7907216
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Role of D1 receptor mechanisms in the potentiation of motor responses to L-dopa and apomorphine by MK 801 in the reserpine-treated mouse.
    Kaur S; Starr MS; Starr BS
    J Neural Transm Park Dis Dement Sect; 1994; 8(1-2):107-16. PubMed ID: 7893372
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Interactions between metabotropic glutamate 5 and adenosine A2A receptors in normal and parkinsonian mice.
    Kachroo A; Orlando LR; Grandy DK; Chen JF; Young AB; Schwarzschild MA
    J Neurosci; 2005 Nov; 25(45):10414-9. PubMed ID: 16280580
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Influence of previous exposure to levodopa on the interaction between dizocilpine and dopamine D1 and D2 agonists in rats with 6-hydroxydopamine-induced lesions.
    Boldry RC; Chase TN; Engber TM
    J Pharmacol Exp Ther; 1993 Dec; 267(3):1454-9. PubMed ID: 7903390
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dynorphin A(1-13) preferentially inhibits behaviors induced by the D2 dopamine agonist RU 24213 but not by the D1 dopamine agonist SK&F 38393.
    Ukai M; Toyoshi T; Kameyama T
    Pharmacol Biochem Behav; 1992 Aug; 42(4):755-9. PubMed ID: 1355296
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Motor responses to dopamine D1 and D2 agonists in the reserpine-treated mouse are affected differentially by the NMDA receptor antagonist MK 801.
    Goodwin P; Starr BS; Starr MS
    J Neural Transm Park Dis Dement Sect; 1992; 4(1):15-26. PubMed ID: 1531757
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Reversal of reserpine-induced catalepsy by selective D1 and D2 dopamine agonists.
    Hubbard CA; Trugman JM
    Mov Disord; 1993 Oct; 8(4):473-8. PubMed ID: 7901761
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.